
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is well-positioned for future growth as it anticipates securing additional human licensing deals in 2026, which could significantly enhance topline revenue. The company offers a unique approach in the liquid biopsy market by focusing on circulating cell-free nucleoproteins, and recent validation studies suggest promising early-stage detection capabilities, especially in colorectal and lung cancers. Furthermore, the combination of rigorous validation from reputable institutions and advanced technology for high-purity circulating tumor DNA datasets supports VolitionRX's competitive edge, potentially increasing clinical adoption and establishing new revenue streams in diagnostics.
Bears say
VolitionRX Ltd faces several critical threats that contribute to a negative outlook on its stock, including potential failures in clinical development of its diagnostic products and challenges in securing necessary license agreements. Additionally, the company reported a notable net loss of $23.4 million, translating to a loss of $0.22 per share, indicating financial strain that could hinder its operations. The persistent issues related to achieving market traction for its products, compounded by risks of dilution and potential delisting, further raise concerns regarding the viability of its business model.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares